Potential role of mammalian target of rapamycin inhibitors in breast cancer therapy

Clinical Breast Cancer

Volumn 6, Issue 4, 2005, Pages 357-360

  Meric Bernstam, Funda ^a   Esteva, Francisco J ^a  

^a UNIVERSITY OF TEXAS   (United States)

Author keywords

Akt; Molecular therapeutics; Targeted therapy; Translation

Indexed keywords

CARBOPLATIN; CYCLIN D1; DOXORUBICIN; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTROGEN; ESTROGEN RECEPTOR; EVEROLIMUS; FK 506 BINDING PROTEIN; GEMCITABINE; HYPOXIA INDUCIBLE FACTOR 1; INITIATION FACTOR 4E BINDING PROTEIN 1; LETROZOLE; MAMMALIAN TARGET OF RAPAMYCIN; MESSENGER RNA; NAVELBINE; PACLITAXEL; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; PROTEIN BCL 2; PROTEIN KINASE B; PROTEIN S6; RAPAMYCIN; RAPAMYCIN DERIVATIVE; S6 KINASE; TAMOXIFEN; TEMSIROLIMUS; TRASTUZUMAB;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; BREAST CANCER; CANCER HORMONE THERAPY; CANCER INHIBITION; CANCER RECURRENCE; CANCER REGRESSION; CANCER RELAPSE; CLINICAL TRIAL; DOSE RESPONSE; DRUG BINDING; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG ERUPTION; DRUG MEGADOSE; DRUG POTENTIATION; ENZYME ACTIVATION; FEEDBACK SYSTEM; GENE OVEREXPRESSION; GLIOBLASTOMA; HUMAN; MANTLE CELL LYMPHOMA; METASTASIS POTENTIAL; MUCOSA INFLAMMATION; NONHUMAN; NOTE; PROTEIN EXPRESSION; PROTEIN FUNCTION; SIDE EFFECT; SIGNAL TRANSDUCTION; STOMATITIS; TREATMENT OUTCOME;

EID: 28344442000     PISSN: 15268209     EISSN: None     Source Type: Journal    
DOI: 10.3816/CBC.2005.n.041     Document Type: Note

References (40)

1. Hahn-Windgassen A, Nogueira V, Chen CC, et al. Akt activates mTOR by regulating cellular ATP and AMPK activity. J Biol Chem 2005; In Press.
2. Kevil CG, De Benedetti A, Payne DK, et al. Translational regulation of vascular permeability factor by eukaryotic initiation factor 4E: implications for tumor angiogenesis. Int J Cancer 1996; 65:785-790.
3. Sarbassov DD, Ali SM, Kim DH, et al. Rictor, a novel binding partner of mTOR, defines a rapamycin-insensitive and raptor-independent pathway that regulates the cytoskeleton. Curr Biol 2004; 14:1296-1302.
4. Sarbassov DD, Guertin DA, Ali SM, et al. Phosphorylation and regulation of Akt/PKB by the rictor-mTOR complex. Science 2005; 307:1098-1101.
5. Steck PA, Pershouse MA, Jasser SA, et al. Identification of a candidate tumour suppressor gene, MMAC1, at chromosome 10q23.3 that is mutated in multiple advanced cancers. Nat Genet 1997; 15:356-362.
6. Perren A, Weng LP, Boag AH, et al. Immunohistochemical evidence of loss of PTEN expression in primary ductal adenocarcinomas of the breast. Am J Pathol 1999; 155:1253-1260.
7. Rhei E, Kang L, Bogomolniy F, et al. Mutation analysis of the putative tumor suppressor gene PTEN/MMAC1 in primary breast carcinomas. Cancer Res 1997; 57:3657-3659.
8. Khan S, Kumagai T, Vora J, et al. PTEN promoter is methylated in a proportion of invasive breast cancers. Int J Cancer 2004; 112:407-410.
9. Tsutsui S, Inoue H, Yasuda K, et al. Reduced expression of PTEN protein and its prognostic implications in invasive ductal carcinoma of the breast. Oncology 2005; 68:398-404.
10. Saal LH, Holm K, Maurer M, et al. PIK3CA mutations correlate with hormone receptors, node metastasis, and ERBB2, and are mutually exclusive with PTEN loss in human breast carcinoma. Cancer Res 2005; 65:2554-2559.
11. Zhou BP, Hu MC, Miller SA, et al. HER-2/neu blocks tumor necrosis factor-induced apoptosis via the Akt/NF-kappaB pathway. J Biol Chem 2000; 275:8027-8031.
12. Cui X, Zhang P, Deng W, et al. Insulin-like growth factor-I inhibits progesterone receptor expression in breast cancer cells via the phosphatidylinositol 3-kinase/Akt/mammalian target of rapamycin pathway: progesterone receptor as a potential indicator of growth factor activity in breast cancer. Mol Endocrinol 2003; 17:575-588.
13. Chung J, Bachelder RE, Lipscomb EA, et al. Integrin (alpha 6 beta 4) regulation of eIF-4E activity and VEGF translation: a survival mechanism for carcinoma cells. J Cell Biol 2002; 158:165-174.
14. Avdulov S, Li S, Michalek V, et al. Activation of translation complex eIF4F is essential for the genesis and maintenance of the malignant phenotype in human mammary epithelial cells. Cancer Cell 2004; 5:553-563.
15. Barlund M, Forozan F, Kononen J, et al. Detecting activation of ribosomal protein S6 kinase by complementary DNA and tissue microarray analysis. J Natl Cancer Inst 2000; 92:1252-1259.
16. Li BD, McDonald JC, Nassar R, et al. Clinical outcome in stage I to III breast carcinoma and eIF4E overexpression. Ann Surg 1998; 227:756-763.
17. Noh WC, Mondesire WH, Peng J, et al. Determinants of rapamycin sensitivity in breast cancer cells. Clin Cancer Res 2004; 10:1013-1023.
18. Zhou X, Tan M, Stone Hawthorne V, et al. Activation of the Akt/mammalian target of rapamycin/4E-BP1 pathway by ErbB2 overexpression predicts tumor progression in breast cancers. Clin Cancer Res 2004; 10:6779-6788.
19. Majumder PK, Febbo PG, Bikoff R, et al. mTOR inhibition reverses Akt-dependent prostate intraepithelial neoplasia through regulation of apoptotic and HIF-1-dependent pathways. Nat Med 2004; 10:594-601.
20. Yu K, Toral-Barza L, Discafani C, et al. mTOR, a novel target in breast cancer: the effect of CCI-779, an mTOR inhibitor, in preclinical models of breast cancer. Endocr Relat Cancer 2001; 8:249-258.
21. Mondesire WH, Jian W, Zhang H, et al. Targeting mammalian target of rapamycin synergistically enhances chemotherapy-induced cytotoxicity in breast cancer cells. Clin Cancer Res 2004; 10:7031-7042.
22. Raymond E, Alexandre J, Faivre S, et al. Safety and pharmacokinetics of escalated doses of weekly intravenous infusion of CCI-779, a novel mTOR inhibitor, in patients with cancer. J Clin Oncol 2004; 22:2336-2347.
23. Witzig TE, Geyer SM, Ghobrial I, et al. Phase II trial of single-agent temsirolimus (CCI-779) for relapsed mantle cell lymphoma. J Clin Oncol 2005; 23:5347-5356.
24. Galanis E, Buckner JC, Maurer MJ, et al. Phase II trial of temsirolimus (CCI-779) in recurrent glioblastoma multiforme: a North Central Cancer Treatment Group study. J Clin Oncol 2005; 23:5294-5304.
25. Atkins MB, Hidalgo M, Stadler WM, et al. Randomized phase II study of multiple dose levels of CCI-779, a novel mammalian target of rapamycin kinase inhibitor, in patients with advanced refractory renal cell carcinoma. J Clin Oncol 2004; 22:909-918.
26. Chan S, Scheulen ME, Johnston S, et al. Phase II study of temsirolimus (CCI-779), a novel inhibitor of mTOR, in heavily pretreated patients with locally advanced or metastatic breast cancer. J Clin Oncol 2005; 23:5314-5322.
27. Baker AF, Dragovich T, Ihle NT, et al. Stability of phosphoprotein as a biological marker of tumor signaling. Clin Cancer Res 2005; 11:4338-4340.
28. Barlund M, Monni O, Kononen J, et al. Multiple genes at 17q23 undergo amplification and overexpression in breast cancer. Cancer Res 2000; 60:5340-5344.
29. Gera JF, Mellinghoff IK, Shi Y, et al. AKT activity determines sensitivity to mammalian target of rapamycin (mTOR) inhibitors by regulating cyclin D1 and c-myc expression. J Biol Chem 2004; 279:2737-2746.
30. Dong J, Peng J, Zhang H, et al. Role of glycogen synthase kinase 3beta in rapamycin-mediated cell cycle regulation and chemosensitivity. Cancer Res 2005; 65:1961-1972.
31. Dong D, Ko B, Baumeister P, et al. Vascular targeting and antiangiogenesis agents induce drug resistance effector GRP78 within the tumor microenvironment. Cancer Res 2005; 65:5785-5791.
32. Hashemolhosseini S, Nagamine Y, Morley SJ, et al. Rapamycin inhibition of the G1 to S transition is mediated by effects on cyclin D1 mRNA and protein stability. J Biol Chem 1998; 273:14424-14429.
33. Neshat MS, Mellinghoff IK, Tran C, et al. Enhanced sensitivity of PTEN-deficient tumors to inhibition of FRAP/mTOR. Proc Natl Acad Sci U S A 2001; 98:10314-10319.
34. Shi Y, Gera J, Hu L, et al. Enhanced sensitivity of multiple myeloma cells containing PTEN mutations to CCI-779. Cancer Res 2002; 62:5027-5034.
35. Sun SY, Rosenberg LM, Wang X, et al. Activation of Akt and eIF4E survival pathways by rapamycin-mediated mammalian target of rapamycin inhibition. Cancer Res 2005; 65:7052-7058.
36. Tabernero J, Rojo F, Burris H, et al. A phase I study with tumor molecular pharmacodynamic (MPD) evaluation of dose and schedule of the oral mTOR-inhibitor Everolimus (RAD001) in patients (pts) with advanced solid tumors. J Clin Oncol 2005; 23(16 suppl):193s (Abstract #3007).
37. Nagata Y, Lan KH, Zhou X, et al. PTEN activation contributes to tumor inhibition by trastuzumab, and loss of PTEN predicts trastuzumab resistance in patients. Cancer Cell 2004; 6:117-127.
38. deGraffenried LA, Friedrichs WE, Russell DH, et al. Inhibition of mTOR activity restores tamoxifen response in breast cancer cells with aberrant Akt activity. Clin Cancer Res 2004; 10:8059-8067.
39. Boulay A, Rudloff J, Ye J, et al. Dual inhibition of mTOR and estrogen receptor signaling in vitro induces cell death in models of breast cancer. Clin Cancer Res 2005; 11:5319-5328.
40. National Institutes of Health [Website]. Available at http://www.clinical-trials.gov/ct/gui/show/NCT00083993. Accessed: October 9, 2005.